RISalud
Institutional Health Repository of Andalucía
Please use this identifier to cite or link to this item:
http://hdl.handle.net/10668/2053| Title: | Left ventricular assist device. |
| Authors: | Jiménez-Navarro, Manuel Molero, Encarnación Teresa, Eduardo de |
| metadata.dc.contributor.authoraffiliation: | [Jiménez-Navarro,M; Molero,E; Teresa,E de] Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain. |
| Keywords: | Inhibidores de la enzima convertidora de angiotensina;Insuficiencia cardíaca;Corazón Auxiliar;Antagonistas Adrenérgicos beta;Espironolactona |
| metadata.dc.subject.mesh: | Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protease Inhibitors::Angiotensin-Converting Enzyme Inhibitors Medical Subject Headings::Diseases::Cardiovascular Diseases::Heart Diseases::Heart Failure Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures, Operative::Assisted Circulation::Heart-Assist Devices Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans Medical Subject Headings::Chemicals and Drugs::Organic Chemicals::Lactones::Spironolactone Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Neurotransmitter Agents::Adrenergic Agents::Adrenergic Antagonists::Adrenergic beta-Antagonists |
| Issue Date: | 28-Mar-2002 |
| Publisher: | Massachusetts Medical Society |
| Citation: | Jiménez-Navarro M, Molero E, Teresa E de. Left ventricular assist device. N. Engl. J. Med.. 2002; 346(13):1023-5; author reply 1023-5 |
| Abstract: | To the Editor: The value of angiotensin-converting– enzyme (ACE) inhibitors, beta-blockers, and spironolactone has been well established by the results of numerous clinical trials. About 70 percent of the patients described by Rose et al. were treated with ACE inhibitors or angiotensin II–receptor antagonists; 35 to 40 percent received spironolactone, and only about 20 percent received beta-blockers. Thus, this population cannot have been considered to be optimally treated from the point of view of medical therapy. |
| URI: | http://hdl.handle.net/10668/2053 |
| metadata.dc.relation.publisherversion: | http://www.nejm.org/doi/full/10.1056/NEJM200203283461313 |
| ISSN: | 1533-4406 (Online) 0028-4793 (Print) |
| Appears in Collections: | 01- Artículos - Hospital Virgen de la Victoria |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Jimenez_Left.pdf | Carta publicada | 80,94 kB | Adobe PDF | View/Open |
This item is protected by original copyright |
This item is licensed under a Creative Commons License
